2023 Luxembourg Pharmaceuticals Stock List
Pharmaceutical industry operation is relatively stable, the first quarter of the pharmaceutical manufacturing industry revenue and profit growth of 16% and 19%, respectively, during the same period of listed companies plate excluding non-recurring gains profit growth of 25% year-on-year, the main industry is running in good condition. The following is a list of stocks of LUXEMBOURG pharmaceuticals that I hope will be helpful to you!
Pharmaceutical plate stocks are:
Chemical pharmaceuticals, traditional Chinese medicine, biological products, pharmaceutical business, medical equipment and other pharmaceutical industry;
Chinese medicine industry:
600211 Tibet Pharmaceuticals, 600285 Antelope shares, 000423 Dong'ahjiao, 000650 ST Renhe, 600422 Kunming Pharmaceutical, 600085 Tongrentang, 000790 Huashen Group, 600557 Kangyuan Pharmaceutical, 600572 Kang Enbei, 000607 Huali Pharmaceutical, 000538 Yunnan Baiyao, 600129 Taiji Group, 600750 Jiangzhong Pharmaceutical, 600594 Yibai Pharmaceutical, 600436 Pientzehuang, 600781 Shanghai Auxin, 000989 Jiuzhitang, 002118 Zixin Pharmaceutical, 000919 Jinling Pharmaceutical, 600535 Ma Yinglong, 600351 Yabao Pharmaceutical, 000590 Ziguang Guhan;
Chemical Pharmaceuticals Industry:
600771 Dongsheng Science and Technology, 000597 Northeast Pharmaceutical, 600829 Sanjing Pharmaceutical, 600812 North China Pharmaceutical, 600488 Tianyao Pharmaceutical, 002019 Xinfu Pharmaceutical, 600252 Zhongheng Group, 600276 Hengrui Pharmaceutical, 000952 Guangji Pharmaceutical, 600521 Huahai Pharmaceutical, 600267 Haizheng Pharmaceutical, 600842 Chinese and Western Pharmaceutical, 600666 Southwest Pharmaceutical, 600518 Kangmei Pharmaceutical, 000627 Tianmao Group, 000739 Pulokangyu, 002099 Haixiang Pharmaceuticals, 002004 Huabang Pharmaceuticals, 002001 Xinhecheng, 000756 Xinhua Pharmaceuticals, 600420 Hyundai Pharmaceuticals;
Biologics Industry:
600867 Tonghua Dongbao, 000416 KENT Bio, 002038 Shuanglu Pharmaceuticals, 600201 Jinyu Group, 002007 Hualan Bio, 600195 Zhongmu Shares, 600161 Tiantan Bio, 600196 Fosun Pharmaceuticals;
Medical Device Industry:
1, Wandong Medical (600055): Medical X-ray machine domestic first, China Resources for the controlling shareholder;
2, Xinhua Medical (600587): cleaner and sterilizer to fill the gaps in the country, Zizi Group for the controlling shareholder;
3, Yueyue Medical (002223): stethoscope, blood pressure meter, oxygen concentrator, wheelchair car
4, Lepu Medical (300003): intravascular drug elution Stent system
5, Yang Pu medical (300030): the third generation of vacuum blood collection system
6, Xinlitai (002294): high-end medical equipment
7, Hainan Haiyao medicine (000566): cochlear implants
8, Shandong Pharmaceutical Glass (600529): medicinal glass
9, People's Republic of China ( 600079): anesthesia, fertility regulator, Uygur medicine
Pharmaceutical business industry:
000963 East China Pharmaceutical, 600763 Tongze Medical, 600511 State Pharmaceuticals Corporation, 000028 Consistent Pharmaceuticals
Pharmaceutical Business Concepts
Pharmaceutical business concept of the so-called "three parties", "four countries"
Three parties: State Pharmaceuticals, Shanghai Pharmaceuticals, Jiuzhou Tong;
Four countries: State Pharmaceuticals, Shanghai Pharmaceuticals, China Resources, Jiuzhou Tong;
State Pharmaceutical Department:
1, China Pharmaceutical (600056): General Meikang in the national pharmaceutical and health products industry import and export total ranking of Chinese enterprises ranked No. 1, the whole industry ranked No. 3;
2, State Pharmaceutical Corporation (600511): the company is the State Drug Administration identified 41 drugs national cross-provincial retail chain of pilot enterprises, 8 drug e-commerce pilot One of the enterprises; controlling shareholder of Sinopharm Holdings (HK1099);
3, consistent pharmaceutical (000028): holding 100% equity in Sinopharm Holdings Guangzhou, Sinopharm Guangzhou is the core enterprise of Sinopharm Holdings in southern China, with more than 800 pharmaceutical commercial distribution network, covering 29 provinces, cities and districts of the country's large and medium-sized cities; through the acquisition, the company's main business income will be expanded from 1.576 billion yuan to nearly 5 billion yuan; at the end of 08, the company acquired 100% equity of Sinopharm Holdings Nanning Co., Ltd. with 136.67 million yuan, 75% equity of Suzhou Wanqing Pharmaceutical Co., Ltd. and 100% equity of Dongguan Dongfeng TCM Co., Ltd. and at the end of August, the company acquired 100% equity of Guangxi Unanimous Pharmaceutical with 5 million yuan; the controlling shareholder is Sinopharm Holdings (HK1099);
4, Fosun Pharmaceuticals (600196): 34.66% stake in Sinopharm Holdings (HK1099) to maintain China's drug distribution No. 1 position;
5, Shanghai Pharmaceuticals (601607):
6, Jiuzhoutong (600998): the country's third largest pharmaceutical business, the first private pharmaceutical business;
7, Nanjing Medicine (600713): the country's fourth largest pharmaceutical distribution enterprises;
8, the first medicine (600833): Shanghai's second largest pharmaceutical distribution enterprises;
9, Tongrentang (600085): with nearly 500 "Beijing Tongrentang stores" and nearly 1,000 image counters; the group also opened 20 stores in 13 countries and regions around the world;
10, Jiasitang (002462), Beijing's largest pharmaceutical business;
(1) Puro shares, Northeast Pharmaceuticals: adamantanes - antiviral drugs
(2) Shanghai Pharmaceuticals: the drug Tamiflu is an antiviral drug, this drug is Roche's patented drug, in the domestic authorization of Shanghai Pharmaceuticals parent company of Shanghai Pharmaceutical Group under the Shanghai 3D Pharmaceuticals has the production of
(3) Rheinland Biologicals: the production of anise extract, this extract can be used as a raw material for the production of Tamiflu;
(4) Baiyunshan A, Tongrentang: Panax quinquefolium as a drug that enhances the human body's self-immunity is also one of the main drugs to fight against viruses. one of the main drugs
(5) Zhongmu shares, Jinyu Group: these two companies are big producers of animal vaccines;
(6) Tiantan Bio, Hualan Bio: these two companies can produce human influenza vaccine;
(7) Daan Genetics, Kewa Bio: these two companies produce diagnostic reagents;
(8) LUXI Pharmaceuticals: bio-fermentation and bio-synthesis and other anti-infectious drug production;
(9) LUXI Pharmaceuticals: biofermentation and bio-synthesis and other anti-infectious drug production Synthesis and other anti-infective drug production enterprises, penicillin semi-synthetic drugs, cephalosporin antimicrobials; its subsidiary Sherrill Pharmaceutical Co., Ltd. is an important producer of veterinary drugs in China;
(9) Lianhuan Pharmaceutical: Lianhuan Pharmaceutical and Yangzhou University and other Yangzhou Wake Bioengineering Co. Inactivated vaccine;
Volume and price of the Lubao medicine
1 Lubao medicine's share price but decided by two markets, a securities market, a veterinary medicine API market price.
2And from the veterinary API market competition pattern, 18 August 18 Ningxia government seized shut down the industry leader Terra Pharma is located in Yongning plant fermentation tanks, involving the plant at least 5000 tons of production capacity, while the industry's entire production capacity of about 16,000 tons, nearly 1/3 of the production capacity has been shut down. The current nominal capacity distribution is as follows: Terra remaining about 4,500 tons, Qilu Pharmaceuticals about 3,300 tons, Lubao Pharmaceuticals about 3,000 tons. It is projected that the actual effective production capacity of Lubao has been more than 30%, and the industry pattern has changed abruptly.
3 some time ago, the stock price of the price increase is also fully embodied in the expectations, and veterinary raw materials spot market price changes are not large, spot prices do not rise is a negative, because there is a difference between the market expectations, coupled with the entire securities market downturn, the recent stock price has fallen back.
4 industry leader Terra Pharmaceuticals should be put back into production within a year is difficult to realize, otherwise it will not be because of environmental issues legal person in prison, officials removed from office. Explain the solution to the environmental problem is very difficult. And now it should be the stage of consumption of inventory. Once the inventory consumption for a period of time, the product price increase is inevitable.
5 the next period of time the trend upward should not change, down is the opportunity to build a position
6 the biggest risk from the industry leader Terra Pharmaceuticals re-commissioning